Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.67 +5.21%
EPS Growth %: -138.7%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: -138.7%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.
The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teradyne (TER) Tops Q3 EPS by 21c, Beats on Revenue; Offers Q4 EPS Guidance
- Miv Therapeutics, Inc. (IVT) Tops Q3 EPS by 21c; Offers Guidance
- Zurn Water Solutions Corporation (ZWS) Tops Q3 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
